该药的两大亮点除了靶点是PD-L1,更重要的是单域单抗,又称纳米抗体(nanobody)或重链抗体(heavy chain antibody,hcAb)。 与传统抗体不同的是,单域单抗的体积约为传统抗体的1/10且仅由重链构成,其抗原结合区仅是一个通过铰链区与Fc区连接的单结构域,而且这个抗原结合区自抗体上分离后仍具有结合抗原的功能,这就...
近日,中国科学院上海药物研究所宫丽崑课题组、李佳课题组以及深圳大学靳广毅课题组合作开发了PD-L1/TLR7双靶向纳米抗体偶联药物(Nanobody drug conjugate,NDC),其可通过重塑肿瘤免疫微环境发挥强劲抗肿瘤作用,并显示出临床开发的前景。该研...
该药的两大亮点除了靶点是PD-L1,更重要的是单域单抗,又称纳米抗体(nanobody)或重链抗体(heavy chain antibody,hcAb)。 与传统抗体不同的是,单域单抗的体积约为传统抗体的1/10且仅由重链构成,其抗原结合区仅是一个通过铰链区与Fc区连接的单结构域,而且这个抗原结合区自抗体上分离后仍具有结合抗原的功能,这就...
[7]Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade[J]. Cell Discovery, 2017, 3:17004. [8]江苏康宁杰瑞皮下注射PD-L1抗体KN035的临床数据将在ASCO大会发布. [EB/OL]. [2020-08-11]. http://www.alphamabonc.com/html/news/2130...
[7]Zhang F, Wei H, Wang X, et al. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade[J]. Cell Discovery, 2017, 3:17004. [8]江苏康宁杰瑞皮下注射PD-L1抗体KN035的临床数据将在ASCO大会发布. [...
近日，中国科学院上海药物研究所宫丽崑课题组、李佳课题组以及深圳大学靳广毅课题组合作开发了PD-L1/TLR7双靶向纳米抗体偶联药物（Nanobody drug conjugate，NDC），其可通过重塑肿瘤免疫微环境发挥强劲抗肿瘤作用，并显示出临床开发的前景。该研究论文于2022年10月17日在线发表于Journal for Immunotherapy of Cancer。研...
参考文献:Liu M, Jin D, Yu W, Yu J, Cao K, Cheng J, Zheng X, Wang A, Liu Y. Enhancing Tumor Immunotherapy by Multivalent Anti-PD-L1 Nanobody Assembled via Ferritin Nanocage. Adv Sci (Weinh). 2024 May;11(20):e2308248. doi: 10.1002/advs.202308248. Epub 2024 Mar 16. PMID: 38...
[5] RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer. Retrieved October 9, 2023, from https://www.globenewswire.com/news-release/2023/10/09/2756594/0/en/RAD-receives-approval-for-Phase-1-therapeutic-study-of-PDL1-nanobody-in-Non-Small-...
[5] RAD receives approval for Phase 1 therapeutic study of PDL1-nanobody in Non-Small Cell Lung Cancer. Retrieved October 9, 2023, from https://www.globenewswire.com/news-release/2023/10/09/2756594/0/en/RAD-receives-approval-for-Phase-1-therapeutic-study-of-PDL1-nanobody-in-Non-Small-...
Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade(2017); Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpointtherapy(2019); Crystal clear=visualizing the intervention mechanism of the PD-1 PD-L1 interaction by ...